Nuo Therapeutics (AURX)
OTHER OTC:AURX
US Market

Nuo Therapeutics (AURX) Income Statement

10 Followers

Nuo Therapeutics Income Statement

Last quarter (Q ), Nuo Therapeutics's total revenue was $197.01K, an increase of 166.24% from the same quarter last year. In Q, Nuo Therapeutics's net income was $-653.15K. See Nuo Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 18
Total Revenue
$ 608.52K$ 608.52K$ 112.25K-$ 0.00$ 1.37M
Cost of Revenue
$ -126.09K$ -126.09K$ 19.21K-$ 0.00$ 162.99K
Gross Profit
$ 734.62K$ 734.62K$ 93.04K-$ 0.00$ 1.21M
Operating Expense
$ -3.65M$ -3.65M$ 3.41M$ 90.67K$ 378.06K$ 2.71M
Operating Income
$ -3.17M$ -3.17M$ -3.32M$ -90.67K$ -378.06K$ -1.50M
Net Non Operating Interest Income Expense
$ -3.16K$ -3.16K$ -2.10K-$ -48.39K$ -38.89K
Other Income Expense
--$ -4.52K-$ 335.58K$ 1.76K
Pretax Income
$ -3.17M$ -3.17M$ -3.17M$ -90.67K$ -90.87K$ -1.54M
Tax Provision
--$ -1.99M$ -21.05K$ 0.00$ 0.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -3.17M$ -3.17M$ -3.17M$ -886.26K$ 7.71M$ -1.54M
Basic EPS
$ -0.08$ -0.08$ -0.08$ -0.03$ 0.30$ -0.07
Diluted EPS
$ -0.08$ -0.08$ -0.08$ -0.03$ 0.27$ -0.07
Basic Average Shares
$ 168.31M$ 42.08M$ 40.00M$ 30.30M$ 25.69M$ 23.28M
Diluted Average Shares
$ 168.31M$ 42.08M$ 40.00M$ 3.02M$ 27.31M$ 23.28M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ -3.78M$ -3.78M$ 3.43M$ 90.67K$ 378.06K$ 2.88M
Net Income From Continuing And Discontinued Operation
$ -3.17M$ -3.17M$ -3.17M$ -90.67K$ -90.87K$ -1.54M
Normalized Income
$ -1.83M$ -2.51M--$ -426.45K$ -1.54M
Interest Expense
----$ 48.39K$ 38.89K
EBIT
$ -3.17M$ -3.17M$ -3.17M$ -90.67K$ -42.48K$ -1.50M
EBITDA
$ -3.07M$ -3.07M$ -3.10M$ -90.67K$ -42.48K$ -1.40M
Currency in USD

Nuo Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis